Skip to content
Triangle logo TriangleGet started
← Full study record

NCT01613599 · BASELINE

Baseline characteristics

An Observational Study of The Safety of MabThera/Rituxan (Rituximab) in Participants With Granulomatosis With Polyangiitis (Wegener's) or Microscopic Polyangiitis · Source last updated 2018-07-26

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

denoms
  1. counts
    1. group Id
      BG000
      value
      97
    units
    Participants
groups
  1. description
    Participants with GPA (Wegener's granulomatosis) or MPA who received rituximab as per investigator's discretion were followed for a maximum of 4.32 years.
    id
    BG000
    title
    Rituximab
measures
  1. classes
    1. categories
      1. measurements
        1. group Id
          BG000
          spread
          16.5
          value
          56.3
    dispersion Type
    STANDARD_DEVIATION
    param Type
    MEAN
    title
    Age, Continuous
    unit Of Measure
    years
  2. classes
    1. categories
      1. measurements
        1. group Id
          BG000
          value
          57
        title
        Female
      2. measurements
        1. group Id
          BG000
          value
          40
        title
        Male
    param Type
    COUNT_OF_PARTICIPANTS
    title
    Sex: Female, Male
    unit Of Measure
    Participants
population Description
The safety population included all participants who received any active dose of rituximab.
Complete source fields
denoms
  1. counts
    1. group Id
      BG000
      value
      97
    units
    Participants
groups
  1. description
    Participants with GPA (Wegener's granulomatosis) or MPA who received rituximab as per investigator's discretion were followed for a maximum of 4.32 years.
    id
    BG000
    title
    Rituximab
measures
  1. classes
    1. categories
      1. measurements
        1. group Id
          BG000
          spread
          16.5
          value
          56.3
    dispersion Type
    STANDARD_DEVIATION
    param Type
    MEAN
    title
    Age, Continuous
    unit Of Measure
    years
  2. classes
    1. categories
      1. measurements
        1. group Id
          BG000
          value
          57
        title
        Female
      2. measurements
        1. group Id
          BG000
          value
          40
        title
        Male
    param Type
    COUNT_OF_PARTICIPANTS
    title
    Sex: Female, Male
    unit Of Measure
    Participants
population Description
The safety population included all participants who received any active dose of rituximab.

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice